A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis

CompletadoFase 3ClinicalTrials.gov

ID: NCT00113308Tipo: INTERVENTIONALInicio: 1 de jun de 2005Fin estimado: 1 de sept de 2006

Traducción no disponible, mostrando original

Resumen

This study is being conducted to find out if an investigational drug called GW406381 can help people with rheumatoid arthritis.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Rheumatoid arthritis (RA) for at least 12 months.
Required a non-steroidal anti-inflammatory drug (NSAID) or COX-2 inhibitor for RA for at least 5 out of 7 days of each week for the 4 weeks prior to screening.

Criterios de exclusión

Any history of cardiovascular disease (e.g., heart attack, stroke, congestive heart failure, uncontrolled high blood pressure), documented peripheral arterial insufficiency and symptomatic, clinically significant claudication, or who have a history of peripheral arterial embolism.
Have an active stomach ulcer or history of any stomach tear or bleeding.

Intervenciones

drug

GW406381

Ubicaciones

GSK Investigational Site

Córdoba, Córdoba Province, Argentina

GSK Investigational Site

Córdoba, Córdoba Province, Argentina

GSK Investigational Site

Rosario, Santa Fe Province, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Córdoba, Argentina

GSK Investigational Site

Quilmes, Argentina

GSK Investigational Site

San Juan, Argentina

GSK Investigational Site

San Miguel de Tucumán, Argentina

Patrocinadores

PrincipalGlaxoSmithKline

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase III, 12-Week, Multicentre, Double-Blind, Randomis... | EligiMed